ADARx Pharmaceuticals, Inc. (ADRX) – What Are Investment Firms Thinking About This Stock?

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $35.00.

A number of brokerages recently weighed in on ADRX. TD Cowen began coverage on ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They set a “buy” rating for the company. Zacks Research raised ADARx Pharmaceuticals to a “hold” rating in a research report on Wednesday, October 21st. JPMorgan Chase & Co. began coverage on ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They issued an “overweight” rating and a $38.00 target price on the stock. Wall Street Zen upgraded shares of ADARx Pharmaceuticals to a “hold” rating in a report on Saturday, October 3rd. Finally, UBS Group initiated coverage on shares of ADARx Pharmaceuticals in a report on Tuesday, October 20th. They issued a “buy” rating and a $35.00 target price for the company.

Read Our Latest Stock Report on ADRX

ADARx Pharmaceuticals Price Performance

Shares of NASDAQ:ADRX opened at $14.00 on Tuesday. ADARx Pharmaceuticals has a 52 week low of $12.50 and a 52 week high of $23.21.

ADARx Pharmaceuticals (NASDAQ:ADRX – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($1.34). On average, equities analysts predict that ADARx Pharmaceuticals will post -2.03 EPS for the current fiscal year.

Insider Activity

In other news, Director Erez Chimovits acquired 61,516 shares of the business’s stock in a transaction dated Monday, September 28th. The shares were purchased at an average price of $17.00 per share, with a total value of $1,045,772.00. Following the transaction, the director directly owned 9,292,025 shares in the company, valued at approximately $157,964,425. This represents a 0.67% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Simeon George acquired 1,600,000 shares of the business’s stock in a transaction dated Monday, September 28th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $27,200,000.00. Following the transaction, the director owned 5,554,094 shares in the company, valued at approximately $94,419,598. The trade was a 40.46% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 3,261,516 shares of company stock worth $55,445,772.

Institutional Investors Weigh In On ADARx Pharmaceuticals

A hedge fund recently bought a new position in ADARx Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new position in shares of ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 181,300 shares of the company’s stock, valued at approximately $3,615,000. Goldman Sachs Group Inc. owned approximately 0.17% of ADARx Pharmaceuticals at the end of the most recent quarter.

ADARx Pharmaceuticals Company Profile

(Get Free Report)

ADARx Pharmaceuticals is a clinical-stage biopharmaceutical company developing RNA-targeted medicines for serious diseases. Its research focuses on oligonucleotide therapeutics designed to alter the activity of specific RNA molecules and, in turn, address disease-related gene expression. The company’s pipeline includes investigational candidates for conditions such as hereditary angioedema and complement-mediated diseases. These therapies remain in development and have not been established as approved treatments.

Featured Stories

Analyst Recommendations for ADARx Pharmaceuticals (NASDAQ:ADRX)

Receive News & Ratings for ADARx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADARx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.